Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 76

Sort by

Sort Order Select

Journal Articles

Telomere Length and CD49d Cooperate with IGHV Gene Status As Predictors of Long-Term Progression-Free Survival in CLL Patients Treated with FCR-Based Regimens

Andrea GS Pepper, PhD, Antonella Zucchetto, PhD, Kevin Norris, PhD, Erika Tissino, PhD, Jerry Polesel, Zarni Soe, David Allsup, Anna Hockaday, Pei Loo Ow, Peter Hillmen, MBChB, PhD, Andrew Rawstron, PhD, Daniel Catovsky, MD FRCP, Riccardo Bomben, PhD, Duncan M Baird, PhD, Christopher Fegan, Valter Gattei, MD, Chris Pepper, BSc, PhD

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-141279

Published: 2020

Journal Articles

The Association between Deaths Due to Infection and Mutations of the BRAF, FBXW7, NRAS and XPO1 genes: A Report from the LRF CLL4 Trial

Monica Else, MA,MSc, Stuart J Blakemore, PhD, Jonathan C Strefford, PhD, Daniel Catovsky, MD FRCP

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-134544

Published: 2020

Journal Articles

iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

Michael Hallek, Bruce D. Cheson, Daniel Catovsky, Federico Caligaris-Cappio, Guillermo Dighiero, Hartmut Döhner, Peter Hillmen, Michael Keating, Emili Montserrat, Nicholas Chiorazzi, Stephan Stilgenbauer, Kanti R. Rai, John C. Byrd, Barbara Eichhorst, Susan O’Brien, Tadeusz Robak, John F. Seymour, Thomas J. Kipps

Blood (2018) 131 (25): 2745–2760.

https://doi.org/10.1182/blood-2017-09-806398

Published: 2018

Journal Articles

Clinical Importance of DNA Methylation Signatures in Chronic Lymphocytic Leukaemia Patients Treated with Chemo-Immunotherapy

Blood (2017) 130 (Supplement 1): 56.

https://doi.org/10.1182/blood.V130.Suppl_1.56.56

Published: 2017

Journal Articles

The Contribution of Gene Mutations to Long-Term Clinical Outcomes: Data from the Randomised UK LRF CLL4 Trial

Blood (2017) 130 (Supplement 1): 259.

https://doi.org/10.1182/blood.V130.Suppl_1.259.259

Published: 2017

Journal Articles

Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia

Blood (2017) 129 (5): 553–560.

https://doi.org/10.1182/blood-2016-01-689422

Published: 2017

Journal Articles

Germ line mutations in shelterin complex genes are associated with familial chronic lymphocytic leukemia

Helen E. Speedy, Ben Kinnersley, Daniel Chubb, Peter Broderick, Philip J. Law, Kevin Litchfield, Sandrine Jayne, Martin J. S. Dyer, Claire Dearden, George A. Follows, Daniel Catovsky, Richard S. Houlston

Blood (2016) 128 (19): 2319–2326.

https://doi.org/10.1182/blood-2016-01-695692

Published: 2016

Includes: Supplemental data

Journal Articles

CYP2B6*6 is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia

Gillian G. Johnson, Ke Lin, Trevor F. Cox, Melanie Oates, David R. Sibson, Richard Eccles, Bryony Lloyd, Laura-Jayne Gardiner, Daniel F. Carr, Munir Pirmohamed, Jonathan C. Strefford, David G. Oscier, David Gonzalez de Castro, Monica Else, Daniel Catovsky, Andrew R. Pettitt

Blood (2013) 122 (26): 4253–4258.

https://doi.org/10.1182/blood-2013-07-516666

Published: 2013

Includes: Supplemental data

Journal Articles

ZAP70 Methylation Is An Independent Prognostic Biomarker For Front Line Therapy Of Chronic Lymphocytic Leukemia : Results From The UK LRF CLL4 Trial

Anton Parker, Ben Gregory, Zadie Davis, Monica Else, MA, MSc, Matthew JJ Rose-Zerilli, PhD, Jonathan C Strefford, Daniel Catovsky, MD, DSc(Med), David Oscier

Blood (2013) 122 (21): 4137.

https://doi.org/10.1182/blood.V122.21.4137.4137

Published: 2013

Journal Articles

The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial

David G. Oscier, Matthew J. J. Rose-Zerilli, Nils Winkelmann, David Gonzalez de Castro, Belen Gomez, Jade Forster, Helen Parker, Anton Parker, Anne Gardiner, Andrew Collins, Monica Else, Nicholas C. P. Cross, Daniel Catovsky, Jonathan C. Strefford

Blood (2013) 121 (3): 468–475.

https://doi.org/10.1182/blood-2012-05-429282

Published: 2013

Includes: Supplemental data

Journal Articles

Deregulated Expression of HDAC9 in B-Cells Leads to Lymphoproliferative Disorders As Well As Germinal Center and Post-Germinal Center Derived Lymphomas

Veronica Sylvina Gil, PhD, Sven Stengel, PhD, Govind Bhagat, MD, Louise Howell, BSc, Daniel Catovsky, MD, Laura Pasqualucci, MD, Kevin Petrie, PhD, Arthur Zelent, PhD

Blood (2012) 120 (21): 3505.

https://doi.org/10.1182/blood.V120.21.3505.3505

Published: 2012

Journal Articles

Common variation at 6p21.31 ( BAK1 ) influences the risk of chronic lymphocytic leukemia

Blood (2012) 120 (4): 843–846.

https://doi.org/10.1182/blood-2012-03-413591

Published: 2012

Includes: Supplemental data

Journal Articles

Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route

Claire E. Dearden, Amit Khot, Monica Else, Mike Hamblin, Effie Grand, Ashok Roy, Saman Hewamana, Estella Matutes, Daniel Catovsky

Blood (2011) 118 (22): 5799–5802.

https://doi.org/10.1182/blood-2011-08-372854

Published: 2011

Journal Articles

Telomere Length Is An Independent Predictor of Outcome After Therapy in CLL: Results From the UKCLL4 Trial,

Anton Parker, Jade Forster, Stacey Reichter, David Gonzalez de Castro, PhD, Daniel Catovsky, MD, David Oscier, MD

Blood (2011) 118 (21): 3884.

https://doi.org/10.1182/blood.V118.21.3884.3884

Published: 2011

Journal Articles

Rituximab, Either As Single Agent or in Combination, Is Superior to Other Treatments in Terms of Response Rate and Progression-Free Survival (PFS) in Patients with Splenic Marginal Zone Lymphoma (SMZL)

Ana Marin-Niebla, MD, Monica Else, MA, MSc, Fatima De la Cruz, MD, Paul Batty, MD, Eduardo Rios-Herranz, MD, Claire E. Dearden, Ildefonso Espigado, MD, PhD, Jose Antonio Pérez Simón, MD, PhD, Daniel Catovsky, MD, Estella Matutes

Blood (2011) 118 (21): 4986.

https://doi.org/10.1182/blood.V118.21.4986.4986

Published: 2011

Journal Articles

The Outcome of CLL Patients with 97% Identity to Germline Is Inferior to Other ‘Mutated’ Cases Defined by a 98% Cut off

Zadie Davis, PhD, Anton Parker, Daniel Catovsky, MD, David Oscier, MD

Blood (2011) 118 (21): 2842.

https://doi.org/10.1182/blood.V118.21.2842.2842

Published: 2011

Journal Articles

Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation

Mauricette Michallet, Peter Dreger, Laurent Sutton, Ronald Brand, Sue Richards, Marleen van Os, Mohamad Sobh, Sylvain Choquet, Bernadette Corront, Claire Dearden, Alois Gratwohl, Wolfgang Herr, Daniel Catovsky, Michael Hallek, Theo de Witte, Dietger Niederwieser, Michel Leporrier, Donald Milligan

Blood (2011) 117 (5): 1516–1521.

https://doi.org/10.1182/blood-2010-09-308775

Published: 2011

Journal Articles

Inherited genetic susceptibility to monoclonal B-cell lymphocytosis

Dalemari Crowther-Swanepoel, Tanguy Corre, Amy Lloyd, Gianluca Gaidano, Bianca Olver, Fiona L. Bennett, Chi Doughty, Daniela Toniolo, Federico Caligaris-Cappio, Paolo Ghia, Davide Rossi, Andy C. Rawstron, Daniel Catovsky, Richard S. Houlston

Blood (2010) 116 (26): 5957–5960.

https://doi.org/10.1182/blood-2010-07-294975

Published: 2010

Journal Articles

Response: Defining response criteria in CLL patients treated in clinical research trials

Michael Hallek, Bruce D. Cheson, Daniel Catovsky, Federico Caligaris-Cappio, Guillaume Dighiero, Hartmut Döhner, Peter Hillmen, Michael J. Keating, Emili Montserrat, Kanti R. Rai, Thomas J. Kipps

Blood (2010) 116 (10): 1817–1818.

https://doi.org/10.1182/blood-2010-05-279620

Published: 2010

Journal Articles

Genetic variation in CXCR4 and risk of chronic lymphocytic leukemia

Dalemari Crowther-Swanepoel, Mobshra Qureshi, Martin J. S. Dyer, Estella Matutes, Claire Dearden, Daniel Catovsky, Richard S. Houlston

Blood (2009) 114 (23): 4843–4846.

https://doi.org/10.1182/blood-2009-07-235184

Published: 2009

Includes: Supplemental data

NARROW

Telomere Length and CD49d Cooperate with IGHV Gene Status As Predictors of Long-Term Progression-Free Survival in CLL Patients Treated with FCR-Based Regimens

The Association between Deaths Due to Infection and Mutations of the BRAF, FBXW7, NRAS and XPO1 genes: A Report from the LRF CLL4 Trial

iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

Clinical Importance of DNA Methylation Signatures in Chronic Lymphocytic Leukaemia Patients Treated with Chemo-Immunotherapy

The Contribution of Gene Mutations to Long-Term Clinical Outcomes: Data from the Randomised UK LRF CLL4 Trial

Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia

Germ line mutations in shelterin complex genes are associated with familial chronic lymphocytic leukemia

CYP2B6*6 is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia

ZAP70 Methylation Is An Independent Prognostic Biomarker For Front Line Therapy Of Chronic Lymphocytic Leukemia : Results From The UK LRF CLL4 Trial

The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial

Deregulated Expression of HDAC9 in B-Cells Leads to Lymphoproliferative Disorders As Well As Germinal Center and Post-Germinal Center Derived Lymphomas

Common variation at 6p21.31 ( BAK1 ) influences the risk of chronic lymphocytic leukemia

Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route

Telomere Length Is An Independent Predictor of Outcome After Therapy in CLL: Results From the UKCLL4 Trial,

Rituximab, Either As Single Agent or in Combination, Is Superior to Other Treatments in Terms of Response Rate and Progression-Free Survival (PFS) in Patients with Splenic Marginal Zone Lymphoma (SMZL)

The Outcome of CLL Patients with 97% Identity to Germline Is Inferior to Other ‘Mutated’ Cases Defined by a 98% Cut off

Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation

Inherited genetic susceptibility to monoclonal B-cell lymphocytosis

Response: Defining response criteria in CLL patients treated in clinical research trials

Genetic variation in CXCR4 and risk of chronic lymphocytic leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only